Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 19/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 19/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 17/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 10/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.44 |
| ▸ | PTGFR | P43088 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7804201 | 1.00 | PTGER2 (1.00) | PTGER2PTGER3PTGER4PTGER1PTGDR | |
| SCHEMBL7966426 | 0.90 | PTGER4 (0.82) | PTGER2PTGER3PTGER4PTGER1 | |
| SCHEMBL7947804 | 0.90 | PTGER4 (0.82) | PTGER2PTGER3PTGER4PTGER1 | |
| SCHEMBL7966425 | 0.90 | PTGER4 (0.82) | PTGER2PTGER3PTGER4PTGER1 | |
| SCHEMBL7959170 | 0.89 | PTGER2 (0.80) | PTGER2PTGER3PTGER4PTGER1PTGDR | |
| SCHEMBL7959167 | 0.89 | PTGER2 (0.80) | PTGER2PTGER3PTGER4PTGER1PTGDR | |
| SCHEMBL7966428 | 0.86 | PTGER4 (0.75) | PTGER2PTGER3PTGER4PTGER1 | |
| SCHEMBL7955466 | 0.83 | PTGER2 (0.71) | PTGER2PTGER3PTGER4PTGER1PTGDR | |
| SCHEMBL7955463 | 0.83 | PTGER2 (0.71) | PTGER2PTGER3PTGER4PTGER1PTGDR | |
| SCHEMBL7807282 | 0.81 | PTGER4 (1.00) | PTGER2PTGER3PTGER4PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| EP-1119542-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020371-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER2 2/4885PTGER3 9/4885PTGER4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.